ismagilov Canadian medtech Breathe BioMedical (BRTH), which is developing a breath test for the detection of early-stage breast cancer, has filed to raise around $12M from a US initial public offering. Breathe didn’t disclose any terms in its SEC filing , but indicated in a filing fee schedule that it was looking to raise nearly $12M. Maxim Group is serving as sole bookrunner.
The company hopes to list its shares on Nasdaq under the symbol BRTH. It also intends to seek a listing with the same symbol on a Canadian exchange. Based in New Brunswick, Breathe has been developing a breath test for use as an adjunctive test to mammography for the early detection of breast cancer in dense breast tissue.
The company expects data from a proof-of-concept study to be completed in Q3, with a pivotal trial anticipated in 2026 to support a possible FDA market authorization filing in 2027. More on Renaissance Capital Greenwich Funds - Renaissance IPO ETF Telix, radiopharmaceuticals maker, sets terms for $232M US IPO IPO roundup: Novelis, Waystar Holding, and more Seeking Alpha’s Quant Rating on Renaissance Capital Greenwich Funds - Renaissance IPO ETF.